Please Wait...

SOST // Sclerostin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Scleroteosis is a genetic disorder caused by the loss of the SOST gen product. Studies of this disease characterized, among other clinical features, by progressive bone overgrowth, facial distortion, entrapment of cranial nerves and high intracranial pressure have allowed the identification of the Sclerostin (SOST) protein, which is implicated in the regulation of bone mass (Balemans et al., 2001). SOST is a glycoprotein with a cysteine-knot motif which belongs to the DAN/Cerberus family and is secreted mainly by bone dwelling osteocytes (Veverka et al., 2009). SOST inhibits bone forming activity of osteoblast in vitro, with a mechanism different from the Bone Morphogenetic Protein antagonists (van Bezooijen et al., 2004). Since, SOST have been found to be an endogenous antagonist of the Wnt/β-catenin pathway in the regulation of bone mass (Lin et al., 2009).

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of human SOST in serum.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (5 days ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (1 week ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (2 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (2 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (3 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (3 weeks ago)